Anti-E. coli Antibody Therapeutics
Extraintestinal pathogenic E. coli infections (UTIs, sepsis)
Pre-clinicalActive
Key Facts
Indication
Extraintestinal pathogenic E. coli infections (UTIs, sepsis)
Phase
Pre-clinical
Status
Active
Company
About Austrianni
Austrianni is a private biotech company founded by the creators of the Trianni human antibody platform, focusing on combating tuberculosis and multidrug-resistant extraintestinal pathogenic E. coli infections. The company's core technology enables the isolation of fully human antibodies with extended CDR3 loops for better access to hidden bacterial targets. Austrianni is developing both therapeutic antibodies to treat infections and diagnostic tools for point-of-care testing, positioning itself at the intersection of infectious disease therapeutics and diagnostics.
View full company profile